

Special Issue

Fluctuating Paradigms in Neuroinflammation: Experimental Research Insights for New Clinical Approaches to Multiple Sclerosis

Message from the Guest Editor

Multiple sclerosis (MS), an autoimmune and inflammatory disease of the central nervous system, is characterized by the primary destruction of myelin. The T cell response in MS is regulated at multiple levels, and it depends on the interaction with other immune cells in the periphery as well as with CNS-resident microglia, astrocytes and oligodendrocytes. However, other concomitant unknown neuroinflammatory processes may play a role in the pathogenesis of MS, finally causing myelin disruption, neuronal death, a loss of motor functions and cognitive impairment. In this Special Issue, manuscripts reporting how the new experimental data promote the understanding of pathological processes in neuroinflammation, and how those data generate new clinical approaches to MS, are welcome. We aim at providing a collection of high-impact manuscripts dissecting the unknown or lesser studied neuroinflammatory pathological processes that could lead to a new therapeutical approach to MS. The final goal of this Special Issue is to help neuroscientists to reconsider their basic knowledge of MS.

Guest Editor

Dr. Giovanni Ferrara

Experimental Neuroscience Lab, IRCCS San Martino Hospital, Genoa, Italy

Deadline for manuscript submissions

closed (30 April 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/61552

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).